Dr. Lal Path Labs shares hit 52-week high on highest quarterly revenue growth in 4 years; here's what Morgan Stanley analysts said
NiveshIQ
NSE: LALPATHLAB · Healthcare
Dr. Lal Path Labs Ltd.
₹1,882.50▲ ₹77.30 (+4.28%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on LALPATHLAB. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited (LALPATHLAB) is a leading Indian healthcare company operating laboratories for pathological investigations. The company provides a wide range of pathological and radiological investigations, including bio-chemistry, hematology, histopathology, and more. With a strong presence in India and internationally, LALPATHLAB has been delivering robust revenue and profit growth, driven by strong volume gains and innovation. In Q1 FY27, the company reported 19.1% revenue growth and 31% EBITDA margin, with a 28% YoY jump in profit. The company's strong operational momentum and network growth are expected to drive further growth. With a revenue of ₹2763 Cr and net income of ₹505 Cr, LALPATHLAB is well-positioned for future growth. The company's competitive position is strong, w
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,226 Cr +10.40% | ₹2,462 Cr +10.60% | ₹2,763 Cr +12.20% |
| EBITDA Margin | 27.40% | 28.23% | 31.99% |
| Net Profit | ₹363.00 Cr +50.60% | ₹493.00 Cr +35.80% | ₹509.80 Cr +3.40% |
| EPS | ₹21.43 | ₹29.14 | ₹30.24 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Dr. Lal PathLabs Limited Revenue Breakdown – BSE:LALPATHLAB
LALPATHLAB: Q1 FY27 delivered 19.1% revenue growth and 31% EBITDA margin, with strong volume and innovation
🔒
+ 3 more stories about Dr. Lal Path Labs Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹798 Cr, PAT ₹170 Cr, EPS ₹10.15, EBITDA margin 35.0%. Growth context: revenue QoQ +13.5%, PAT QoQ +29.0%. Street verdict: inline, revenue surprise +5.2%, PAT surprise -7.3%.
Management commentary highlights new capacity additions and capex deployment as key near-term growth drivers, with succe...
FY26 (last completed FY): revenue ₹2, 763 Cr, PAT ₹510 Cr, EBITDA margin 32.0%, EPS ₹30.24. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for LALPATHLAB
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track LALPATHLAB alongside your other holdings
Unlock full LALPATHLAB research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Dr. Lal Path Labs Ltd.?
NiveshIQ detects active intelligence signals for Dr. Lal Path Labs Ltd. (LALPATHLAB) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,759,141.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.